- AbCellera Reports Q1 2024 Business Results
- AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
- AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
- AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
- AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
- AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
- AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
More ▼
Key statistics
On Thursday, Abcellera Biologics Inc (ABCL:NSQ) closed at 3.85, 7.54% above its 52-week low of 3.58, set on May 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.87 |
---|---|
High | 4.01 |
Low | 3.81 |
Bid | 3.80 |
Offer | 4.01 |
Previous close | 3.85 |
Average volume | 1.30m |
---|---|
Shares outstanding | 294.05m |
Free float | 211.77m |
P/E (TTM) | -- |
Market cap | 1.13bn USD |
EPS (TTM) | -0.5056 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼